The novel m6A methyltransferase METTL16 has emerged as a key regulator, modulating the expression of critical target genes and signaling pathways, thereby affecting tumor cell proliferation, chemotherapy sensitivity, and the TME. This evidence concerns the gene METTL16 and neoplasm.